Skip to main content
Year archive

argenx SE — 2026 filings

All 25 regulatory filings released by argenx SE (1AE) in 2026, sourced directly from the official regulator.

25 Filings
2026 Period
2026 filings (25)
Filing Released Lang
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Regulatory Filings
2026-05-11 English
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
Regulatory Filings
2026-05-08 English
6-K - ARGENX SE (0001697862) (Filer)
Foreign Filer Report
2026-05-07 English
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
Regulatory Filings
2026-05-07 English
argenx to Present at BofA Securities 2026 Health Care Conference
Regulatory Filings
2026-05-07 English
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
Regulatory Filings
2026-04-30 English
6-K - ARGENX SE (0001697862) (Filer)
Foreign Filer Report
2026-04-20 English
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Regulatory Filings
2026-04-20 English
argenx announces Annual General Meeting of Shareholders on May 6, 2026
Proxy Solicitation & Information Statement
2026-03-23 English
6-K - ARGENX SE (0001697862) (Filer)
Foreign Filer Report
2026-03-20 English
20-F - ARGENX SE (0001697862) (Filer)
Annual Report FY 2025
2026-03-19 English
6-K - ARGENX SE (0001697862) (Filer)
Foreign Filer Report
2026-03-19 English
argenx SE, Jaarlijkse financiële verslaggeving
Annual Report FY 2025
2026-03-19 English
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
AGM Information
2026-03-06 English
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Earnings Release FY 2025
2026-02-26 English
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Earnings Release Q1 2026
2026-02-26 English
argenx to Present at TD Cowen 46th Annual Healthcare Conference
Regulatory Filings
2026-02-23 English
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
Report Publication Announcement
2026-02-19 English
FORM 6-K
Foreign Filer Report
2026-01-13 English
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
Audit Report / Information Q1 2026
2026-01-13 English
FORM 6-K
Foreign Filer Report
2026-01-12 English
argenx Highlights 2026 Strategic Priorities
Earnings Release FY 2025
2026-01-12 English
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
Investor Presentation
2026-01-06 English
FORM 6-K
Foreign Filer Report
2026-01-05 English
argenx Announces Leadership Transition Marking Next Evolution of Growth
Board/Management Information
2026-01-05 English